<DOC>
	<DOCNO>NCT00658645</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy bifeprunox maintenance phase schizophrenia compare placebo .</brief_summary>
	<brief_title>Efficacy Bifeprunox Patients With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia serious disable mental disorder affect approximately 1 % world 's population . There number antipsychotic drug use none ideal , particular safety profile complex effectiveness limit . In particular , overcome acute exacerbation many patient continue experience significant symptom prevent adequate functioning . In current study , patient suffer schizophrenia currently post-acute maintenance phase disease include . Non-treatment resistant patient include study , since partially respond current antipsychotic treatment still clinically significant symptom and/or impairment function daily life . The study 12-month study initial 12-week placebo-controlled , quetiapine-referenced phase . After initial 12-week phase , patient allocate placebo switch bifeprunox . In final non-inferiority analysis 12-month data , result study combine data similar study ( 11916A ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Main inclusion criteria The subject primary diagnosis schizophrenia The subject experience clinically significant symptom The subject 's medication remain stable 8 week prior screen The subject currently postacute maintenance phase his/her disease Main exclusion criteria The subject significant risk suicide The subject treatment resistant The subject experience acute exacerbation within 8 week prior screen The subject unlikely comply protocol The subject current diagnosis history substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Bifeprunox</keyword>
</DOC>